Aarti Pharmalabs Limited announced the conclusion of the United States Food and Drug Administration (US-FDA) inspection at its Unit-IV facility in Tarapur, Maharashtra, on March 27, 2026. The inspection resulted in the issuance of a single observation noted on Form 483. The company has confirmed that this observation is entirely procedural in nature and assured stakeholders that corrective and preventive actions will be submitted to the US-FDA within the required stipulated period.
Completion of US-FDA Inspection at Tarapur Unit
Aarti Pharmalabs Limited has formally disclosed the outcome of the recent inspection conducted by the United States Food and Drug Administration (US-FDA) at its manufacturing facility, Unit-IV, located in Tarapur, Maharashtra. The inspection concluded on 27th March 2026.
Form 483 Issued
Following the inspection proceedings, the US-FDA issued a ‘Form 483’ document. This document contained only 01 (One) observation. The management has explicitly clarified that this singular observation is procedural in nature, mitigating concerns regarding major compliance failures or critical deficiencies.
Next Steps for Compliance
Aarti Pharmalabs Limited confirms its commitment to adhering to international regulatory standards. The necessary corrective and preventive actions (CAPA) corresponding to the observation, along with full compliance documentation, will be promptly submitted to the US-FDA within the defined regulatory timeline.
Regulatory Disclosure Reference
This notification was made public via disclosures to the stock exchanges, referencing SCRIP CODE: 543748 and SYMBOL: AARTIPHARM, ensuring timely public record keeping.
Source: BSE
